Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression

Oncotarget

Volumn 6, Issue 25, 2015, Pages 20801-20812

  Yang, Liu ^a   Fang, Dongdong ^a   Chen, Huijun ^b   Lu, Yiyu ^a   Dong, Zheng ^c   Ding, Han Fei ^c   Jing, Qing ^d   Su, Shi Bing ^a   Huang, Shuang ^a,c  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CCNE1; Cdk2; Ovarian cancer; Tumor development

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; CYCLIN E1; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CCNE1 PROTEIN, HUMAN; CDK1 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; JNJ-7706621; N-(5-(((5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL)METHYL)THIO)-2-THIAZOLYL)-4-PIPERIDINECARBOXAMIDE; ONCOPROTEIN; OXAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER INHIBITION; CARCINOGENICITY; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVARY TUMOR; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL TIME; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; OXAZOLES; RNA, SMALL INTERFERING; THIAZOLES; TRIAZOLES;

EID: 84940771081     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4600     Document Type: Article

References (34)

1. Jayson GC, Kohn EC, Kitchener HC and Ledermann JA. Ovarian cancer. Lancet. 2014; 384:1376-1388.
2. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih Ie M and Wang TL. Amplicon profiles in ovarian serous carcinomas. Int J Cancer. 2007; 120:2613-2617.
3. Lambros MB, Fiegler H, Jones A, Gorman P, Roylance RR, Carter NP and Tomlinson IP. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. The Journal of pathology. 2005; 205:29-40.
4. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
5. Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P and Mancuso S. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer. 1998; 75:34-39.
6. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K and Miyazaki K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer. 2010; 116:2621-2634.
7. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB and Liu J. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer. 2006; 106:1925-1932.
8. Lv H, Shi Y, Zhang L, Zhang D, Liu G, Yang Z, Li Y, Fei F and Zhang S. Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor. BMC cancer. 2014; 14:576.
9. Sui L, Dong Y, Ohno M, Sugimoto K, Tai Y, Hando T and Tokuda M. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecologic oncology. 2001; 83:56-63.
10. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, et al. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients-a study of the OVCAD consortium. European journal of cancer. 2014; 50:99-110.
11. Siu KT, Rosner MR and Minella AC. An integrated view of cyclin E function and regulation. Cell Cycle. 2012; 11:57-64.
12. Bedrosian I, Lu KH, Verschraegen C and Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 2004; 23:2648-2657.
13. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, Smyth GK and Bowtell DD. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE. 2010; 5:e15498.
14. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009; 15:1417-1427.
15. Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD and Drapkin R. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014; 74:1141-1152.
16. Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, et al. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:5960-5971.
17. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Lohrs U, Amann G and Diebold J. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol. 2006; 126:101-109.
18. Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L and Middleton SA. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005; 65:9038-9046.
19. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V and Plunkett W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009; 113:4637-4645.
20. Chen H, Wu X, Pan ZK and Huang S. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res. 2010; 70:9979-9990.
21. Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, Montag A, Karrison T, Huo D, Rutgers J, Adams S and Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002; 62:6717-6723.
22. Malumbres M and Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9:153-166.
23. Freemantle SJ and Dmitrovsky E. Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer prevention research. 2010; 3:1513-1518.
24. Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL and Newcomb EW. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Human pathology. 2001; 32:808-813.
25. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011; 2:1352-1367.
26. Blagosklonny MV. Do cells need CDK2 and ... Bcr-Abl? Cell death and differentiation. 2004; 11:249-251.
27. Valabrega G, Montemurro F and Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2007; 18:977-984.
28. Pao W and Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature reviews Cancer. 2010; 10(11):760-774.
29. Gray-Schopfer V, Wellbrock C and Marais R. Melanoma biology and new targeted therapy. Nature. 2007; 445:851-857.
30. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine. 1996; 2:561-566.
31. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England journal of medicine. 2001; 344:1031-1037.
32. Hu Q, Lu YY, Noh H, Hong S, Dong Z, Ding HF, Su SB and Huang S. Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene. 2013; 32:3933-3943.
33. Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN, Pan ZK, Dong Z and Huang S. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene. 2009; 28:3047-3057.
34. Hong S, Noh H, Chen H, Padia R, Pan ZK, Su SB, Jing Q, Ding HF and Huang S. Signaling by p38 MAPK Stimulates Nuclear Localization of the Microprocessor Component p68 for Processing of Selected Primary MicroRNAs. Sci Signal. 2013; 6(266):ra16.